Clinuvel Pharmaceuticals Limited (CLVLF)
- Previous Close
0.00 - Open
11.55 - Bid 9.43 x 39400
- Ask 10.58 x 34100
- Day's Range
11.55 - 11.55 - 52 Week Range
8.57 - 11.55 - Volume
3,570 - Avg. Volume
103 - Market Cap (intraday)
488.481M - Beta (5Y Monthly) 0.92
- PE Ratio (TTM)
19.33 - EPS (TTM)
0.48 - Earnings Date Aug 28, 2024
- Forward Dividend & Yield 0.03 (0.37%)
- Ex-Dividend Date Sep 5, 2024
- 1y Target Est
--
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900 and Parvysmelanotide (VLRX001), both alpha-melanocyte stimulating hormone analogue; and PRéNUMBRA, a liquid injectable formulation of afamelanotide. It is also developing NEURACTHEL (ACTH), an adrenocorticotropic hormone to produce cortisol and enables the combat of stress and regulation of immune responses, maintenance of blood pressure, moderation of blood sugar, and regulation of metabolism. The company was incorporated in 1999 and is headquartered in Melbourne, Australia.
www.clinuvel.comRecent News: CLVLF
View MorePerformance Overview: CLVLF
Trailing total returns as of 9/27/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CLVLF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CLVLF
View MoreValuation Measures
Market Cap
488.48M
Enterprise Value
363.66M
Trailing P/E
19.25
Forward P/E
18.98
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
7.78
Price/Book (mrq)
3.32
Enterprise Value/Revenue
6.05
Enterprise Value/EBITDA
9.47
Financial Highlights
Profitability and Income Statement
Profit Margin
40.41%
Return on Assets (ttm)
14.29%
Return on Equity (ttm)
19.39%
Revenue (ttm)
88.18M
Net Income Avi to Common (ttm)
35.64M
Diluted EPS (ttm)
0.48
Balance Sheet and Cash Flow
Total Cash (mrq)
183.87M
Total Debt/Equity (mrq)
0.43%
Levered Free Cash Flow (ttm)
23.45M
Company Insights: CLVLF
CLVLF does not have Company Insights